Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
13,253
archived clinical trials in
Arthritis

Arthrex Eclipse™ Shoulder Prosthesis
A Prospective, Randomized, Multicenter Study Comparing the Safety and Effectiveness of Arthrex's Eclipse™ Shoulder Prothesis to the Univers™ II Shoulder Prosthesis in Patients With a Degenerative Joint Disease
Status: Enrolling
Updated:  12/31/1969
Palmetto Health Orthopedics (formerly Providence Orthopedics Group, LLC_Moore Orthopedics)
mi
from 43215
Columbia, SC
Arthrex Eclipse™ Shoulder Prosthesis
A Prospective, Randomized, Multicenter Study Comparing the Safety and Effectiveness of Arthrex's Eclipse™ Shoulder Prothesis to the Univers™ II Shoulder Prosthesis in Patients With a Degenerative Joint Disease
Status: Enrolling
Updated: 12/31/1969
Palmetto Health Orthopedics (formerly Providence Orthopedics Group, LLC_Moore Orthopedics)
mi
from 43215
Columbia, SC
Click here to add this to my saved trials
Discontinuing NSAIDs
Discontinuing NSAIDs in Veterans With Knee Osteoarthritis
Status: Enrolling
Updated:  12/31/1969
VA Connecticut Healthcare System West Haven Campus, West Haven, CT
535
mi
from 43215
West Haven, CT
Discontinuing NSAIDs
Discontinuing NSAIDs in Veterans With Knee Osteoarthritis
Status: Enrolling
Updated: 12/31/1969
VA Connecticut Healthcare System West Haven Campus, West Haven, CT
535
mi
from 43215
West Haven, CT
Click here to add this to my saved trials
Discontinuing NSAIDs
Discontinuing NSAIDs in Veterans With Knee Osteoarthritis
Status: Enrolling
Updated:  12/31/1969
North Florida/South Georgia Veterans Health System, Gainesville, FL
716
mi
from 43215
Gainesville, FL
Discontinuing NSAIDs
Discontinuing NSAIDs in Veterans With Knee Osteoarthritis
Status: Enrolling
Updated: 12/31/1969
North Florida/South Georgia Veterans Health System, Gainesville, FL
716
mi
from 43215
Gainesville, FL
Click here to add this to my saved trials
Discontinuing NSAIDs
Discontinuing NSAIDs in Veterans With Knee Osteoarthritis
Status: Enrolling
Updated:  12/31/1969
VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA
643
mi
from 43215
Boston, MA
Discontinuing NSAIDs
Discontinuing NSAIDs in Veterans With Knee Osteoarthritis
Status: Enrolling
Updated: 12/31/1969
VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA
643
mi
from 43215
Boston, MA
Click here to add this to my saved trials
Discontinuing NSAIDs
Discontinuing NSAIDs in Veterans With Knee Osteoarthritis
Status: Enrolling
Updated:  12/31/1969
Providence VA Medical Center, Providence, RI
619
mi
from 43215
Providence, RI
Discontinuing NSAIDs
Discontinuing NSAIDs in Veterans With Knee Osteoarthritis
Status: Enrolling
Updated: 12/31/1969
Providence VA Medical Center, Providence, RI
619
mi
from 43215
Providence, RI
Click here to add this to my saved trials
A Prospective, Multicenter Study to Evaluate the ConforMIS iTotal® (CR) Knee Replacement System
A Prospective, Multicenter Study to Evaluate the ConforMIS iTotal® (CR) Knee Replacement System
Status: Enrolling
Updated:  12/31/1969
JFK Medical Center
940
mi
from 43215
Atlantis, FL
A Prospective, Multicenter Study to Evaluate the ConforMIS iTotal® (CR) Knee Replacement System
A Prospective, Multicenter Study to Evaluate the ConforMIS iTotal® (CR) Knee Replacement System
Status: Enrolling
Updated: 12/31/1969
JFK Medical Center
940
mi
from 43215
Atlantis, FL
Click here to add this to my saved trials
A Prospective, Multicenter Study to Evaluate the ConforMIS iTotal® (CR) Knee Replacement System
A Prospective, Multicenter Study to Evaluate the ConforMIS iTotal® (CR) Knee Replacement System
Status: Enrolling
Updated:  12/31/1969
EMMC - Orthopaedic Surgery of Maine
798
mi
from 43215
Bangor, ME
A Prospective, Multicenter Study to Evaluate the ConforMIS iTotal® (CR) Knee Replacement System
A Prospective, Multicenter Study to Evaluate the ConforMIS iTotal® (CR) Knee Replacement System
Status: Enrolling
Updated: 12/31/1969
EMMC - Orthopaedic Surgery of Maine
798
mi
from 43215
Bangor, ME
Click here to add this to my saved trials
A Prospective, Multicenter Study to Evaluate the ConforMIS iTotal® (CR) Knee Replacement System
A Prospective, Multicenter Study to Evaluate the ConforMIS iTotal® (CR) Knee Replacement System
Status: Enrolling
Updated:  12/31/1969
Great Lakes Bone and Joint
197
mi
from 43215
Battle Creek, MI
A Prospective, Multicenter Study to Evaluate the ConforMIS iTotal® (CR) Knee Replacement System
A Prospective, Multicenter Study to Evaluate the ConforMIS iTotal® (CR) Knee Replacement System
Status: Enrolling
Updated: 12/31/1969
Great Lakes Bone and Joint
197
mi
from 43215
Battle Creek, MI
Click here to add this to my saved trials
A Prospective, Multicenter Study to Evaluate the ConforMIS iTotal® (CR) Knee Replacement System
A Prospective, Multicenter Study to Evaluate the ConforMIS iTotal® (CR) Knee Replacement System
Status: Enrolling
Updated:  12/31/1969
Orthopaedic Instatute of Henderson
1751
mi
from 43215
Henderson, NV
A Prospective, Multicenter Study to Evaluate the ConforMIS iTotal® (CR) Knee Replacement System
A Prospective, Multicenter Study to Evaluate the ConforMIS iTotal® (CR) Knee Replacement System
Status: Enrolling
Updated: 12/31/1969
Orthopaedic Instatute of Henderson
1751
mi
from 43215
Henderson, NV
Click here to add this to my saved trials
A Prospective, Multicenter Study to Evaluate the ConforMIS iTotal® (CR) Knee Replacement System
A Prospective, Multicenter Study to Evaluate the ConforMIS iTotal® (CR) Knee Replacement System
Status: Enrolling
Updated:  12/31/1969
Desert Orthopedic Center
1756
mi
from 43215
Las Vegas, NV
A Prospective, Multicenter Study to Evaluate the ConforMIS iTotal® (CR) Knee Replacement System
A Prospective, Multicenter Study to Evaluate the ConforMIS iTotal® (CR) Knee Replacement System
Status: Enrolling
Updated: 12/31/1969
Desert Orthopedic Center
1756
mi
from 43215
Las Vegas, NV
Click here to add this to my saved trials
A Prospective, Multicenter Study to Evaluate the ConforMIS iTotal® (CR) Knee Replacement System
A Prospective, Multicenter Study to Evaluate the ConforMIS iTotal® (CR) Knee Replacement System
Status: Enrolling
Updated:  12/31/1969
Tennessee Orthopaedic Alliance
332
mi
from 43215
Nashville, TN
A Prospective, Multicenter Study to Evaluate the ConforMIS iTotal® (CR) Knee Replacement System
A Prospective, Multicenter Study to Evaluate the ConforMIS iTotal® (CR) Knee Replacement System
Status: Enrolling
Updated: 12/31/1969
Tennessee Orthopaedic Alliance
332
mi
from 43215
Nashville, TN
Click here to add this to my saved trials
A Prospective, Multicenter Study to Evaluate the ConforMIS iTotal® (CR) Knee Replacement System
A Prospective, Multicenter Study to Evaluate the ConforMIS iTotal® (CR) Knee Replacement System
Status: Enrolling
Updated:  12/31/1969
Advanced Orthopedics and Sports Medicine
992
mi
from 43215
Cypress, TX
A Prospective, Multicenter Study to Evaluate the ConforMIS iTotal® (CR) Knee Replacement System
A Prospective, Multicenter Study to Evaluate the ConforMIS iTotal® (CR) Knee Replacement System
Status: Enrolling
Updated: 12/31/1969
Advanced Orthopedics and Sports Medicine
992
mi
from 43215
Cypress, TX
Click here to add this to my saved trials
A Prospective, Multicenter Study to Evaluate the ConforMIS iTotal® (CR) Knee Replacement System
A Prospective, Multicenter Study to Evaluate the ConforMIS iTotal® (CR) Knee Replacement System
Status: Enrolling
Updated:  12/31/1969
Joint Replacement Associates
991
mi
from 43215
Houston, TX
A Prospective, Multicenter Study to Evaluate the ConforMIS iTotal® (CR) Knee Replacement System
A Prospective, Multicenter Study to Evaluate the ConforMIS iTotal® (CR) Knee Replacement System
Status: Enrolling
Updated: 12/31/1969
Joint Replacement Associates
991
mi
from 43215
Houston, TX
Click here to add this to my saved trials
A Prospective, Multicenter Study to Evaluate the ConforMIS iTotal® (CR) Knee Replacement System
A Prospective, Multicenter Study to Evaluate the ConforMIS iTotal® (CR) Knee Replacement System
Status: Enrolling
Updated:  12/31/1969
Mansfield Orthopaedics
619
mi
from 43215
Morrisville, VT
A Prospective, Multicenter Study to Evaluate the ConforMIS iTotal® (CR) Knee Replacement System
A Prospective, Multicenter Study to Evaluate the ConforMIS iTotal® (CR) Knee Replacement System
Status: Enrolling
Updated: 12/31/1969
Mansfield Orthopaedics
619
mi
from 43215
Morrisville, VT
Click here to add this to my saved trials
African American Preference for Knee Replacement: A Patient-Centered Intervention
Behavioral & Social Science Research on Understanding and Reducing Health Disparities
Status: Enrolling
Updated:  12/31/1969
Univ of Pennsylvania
414
mi
from 43215
Philadelphia, PA
African American Preference for Knee Replacement: A Patient-Centered Intervention
Behavioral & Social Science Research on Understanding and Reducing Health Disparities
Status: Enrolling
Updated: 12/31/1969
Univ of Pennsylvania
414
mi
from 43215
Philadelphia, PA
Click here to add this to my saved trials
Zimmer POLAR - Total Knee Arthroplasty (TKA)
Persona Outcomes Led Assessment Research in Total Knee Arthroplasty
Status: Enrolling
Updated:  12/31/1969
Central DuPage Hospital
298
mi
from 43215
Winfield, IL
Zimmer POLAR - Total Knee Arthroplasty (TKA)
Persona Outcomes Led Assessment Research in Total Knee Arthroplasty
Status: Enrolling
Updated: 12/31/1969
Central DuPage Hospital
298
mi
from 43215
Winfield, IL
Click here to add this to my saved trials
Zimmer POLAR - Total Knee Arthroplasty (TKA)
Persona Outcomes Led Assessment Research in Total Knee Arthroplasty
Status: Enrolling
Updated:  12/31/1969
Rothman Institute
450
mi
from 43215
Egg Harbor Township, NJ
Zimmer POLAR - Total Knee Arthroplasty (TKA)
Persona Outcomes Led Assessment Research in Total Knee Arthroplasty
Status: Enrolling
Updated: 12/31/1969
Rothman Institute
450
mi
from 43215
Egg Harbor Township, NJ
Click here to add this to my saved trials
Zimmer POLAR - Total Knee Arthroplasty (TKA)
Persona Outcomes Led Assessment Research in Total Knee Arthroplasty
Status: Enrolling
Updated:  12/31/1969
Duke University
352
mi
from 43215
Durham, NC
Zimmer POLAR - Total Knee Arthroplasty (TKA)
Persona Outcomes Led Assessment Research in Total Knee Arthroplasty
Status: Enrolling
Updated: 12/31/1969
Duke University
352
mi
from 43215
Durham, NC
Click here to add this to my saved trials
Zimmer POLAR - Total Knee Arthroplasty (TKA)
Persona Outcomes Led Assessment Research in Total Knee Arthroplasty
Status: Enrolling
Updated:  12/31/1969
Rothman Institute
416
mi
from 43215
Philadelphia, PA
Zimmer POLAR - Total Knee Arthroplasty (TKA)
Persona Outcomes Led Assessment Research in Total Knee Arthroplasty
Status: Enrolling
Updated: 12/31/1969
Rothman Institute
416
mi
from 43215
Philadelphia, PA
Click here to add this to my saved trials
Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis
A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Efficacy, Safety and Tolerability up to 5 Years in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1666
mi
from 43215
Peoria, AZ
Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis
A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Efficacy, Safety and Tolerability up to 5 Years in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1666
mi
from 43215
Peoria, AZ
Click here to add this to my saved trials
Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis
A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Efficacy, Safety and Tolerability up to 5 Years in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
982
mi
from 43215
Aventura, FL
Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis
A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Efficacy, Safety and Tolerability up to 5 Years in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
982
mi
from 43215
Aventura, FL
Click here to add this to my saved trials
Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis
A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Efficacy, Safety and Tolerability up to 5 Years in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
821
mi
from 43215
Palm Harbor, FL
Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis
A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Efficacy, Safety and Tolerability up to 5 Years in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
821
mi
from 43215
Palm Harbor, FL
Click here to add this to my saved trials
Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis
A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Efficacy, Safety and Tolerability up to 5 Years in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
874
mi
from 43215
Sarasota, FL
Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis
A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Efficacy, Safety and Tolerability up to 5 Years in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
874
mi
from 43215
Sarasota, FL
Click here to add this to my saved trials
Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis
A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Efficacy, Safety and Tolerability up to 5 Years in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
963
mi
from 43215
Tamarac, FL
Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis
A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Efficacy, Safety and Tolerability up to 5 Years in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
963
mi
from 43215
Tamarac, FL
Click here to add this to my saved trials
Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis
A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Efficacy, Safety and Tolerability up to 5 Years in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigational Site
821
mi
from 43215
Tampa, FL
Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis
A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Efficacy, Safety and Tolerability up to 5 Years in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigational Site
821
mi
from 43215
Tampa, FL
Click here to add this to my saved trials
Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis
A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Efficacy, Safety and Tolerability up to 5 Years in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
811
mi
from 43215
Zephyrhills, FL
Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis
A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Efficacy, Safety and Tolerability up to 5 Years in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
811
mi
from 43215
Zephyrhills, FL
Click here to add this to my saved trials
Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis
A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Efficacy, Safety and Tolerability up to 5 Years in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
718
mi
from 43215
Lincoln, NE
Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis
A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Efficacy, Safety and Tolerability up to 5 Years in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
718
mi
from 43215
Lincoln, NE
Click here to add this to my saved trials
Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis
A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Efficacy, Safety and Tolerability up to 5 Years in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
691
mi
from 43215
Omaha, NE
Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis
A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Efficacy, Safety and Tolerability up to 5 Years in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
691
mi
from 43215
Omaha, NE
Click here to add this to my saved trials
Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis
A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Efficacy, Safety and Tolerability up to 5 Years in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
461
mi
from 43215
Freehold, NJ
Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis
A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Efficacy, Safety and Tolerability up to 5 Years in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
461
mi
from 43215
Freehold, NJ
Click here to add this to my saved trials
Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis
A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Efficacy, Safety and Tolerability up to 5 Years in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
414
mi
from 43215
Syracuse, NY
Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis
A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Efficacy, Safety and Tolerability up to 5 Years in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
414
mi
from 43215
Syracuse, NY
Click here to add this to my saved trials
Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis
A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Efficacy, Safety and Tolerability up to 5 Years in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
304
mi
from 43215
Asheville, NC
Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis
A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Efficacy, Safety and Tolerability up to 5 Years in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
304
mi
from 43215
Asheville, NC
Click here to add this to my saved trials
Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis
A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Efficacy, Safety and Tolerability up to 5 Years in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
360
mi
from 43215
Charlotte, NC
Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis
A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Efficacy, Safety and Tolerability up to 5 Years in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
360
mi
from 43215
Charlotte, NC
Click here to add this to my saved trials
Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis
A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Efficacy, Safety and Tolerability up to 5 Years in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
848
mi
from 43215
Oklahoma City, OK
Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis
A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Efficacy, Safety and Tolerability up to 5 Years in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
848
mi
from 43215
Oklahoma City, OK
Click here to add this to my saved trials
Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis
A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Efficacy, Safety and Tolerability up to 5 Years in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
244
mi
from 43215
Duncansville, PA
Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis
A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Efficacy, Safety and Tolerability up to 5 Years in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
244
mi
from 43215
Duncansville, PA
Click here to add this to my saved trials
Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis
A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Efficacy, Safety and Tolerability up to 5 Years in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
427
mi
from 43215
Columbia, SC
Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis
A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Efficacy, Safety and Tolerability up to 5 Years in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
427
mi
from 43215
Columbia, SC
Click here to add this to my saved trials
Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis
A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Efficacy, Safety and Tolerability up to 5 Years in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
360
mi
from 43215
Greenville, SC
Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis
A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Efficacy, Safety and Tolerability up to 5 Years in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
360
mi
from 43215
Greenville, SC
Click here to add this to my saved trials
Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis
A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Efficacy, Safety and Tolerability up to 5 Years in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
901
mi
from 43215
Mesquite, TX
Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis
A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Efficacy, Safety and Tolerability up to 5 Years in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
901
mi
from 43215
Mesquite, TX
Click here to add this to my saved trials
Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis
A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Efficacy, Safety and Tolerability up to 5 Years in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
9463
mi
from 43215
Kogarah,
Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis
A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Efficacy, Safety and Tolerability up to 5 Years in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
9463
mi
from 43215
Kogarah,
Click here to add this to my saved trials
Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis
A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Efficacy, Safety and Tolerability up to 5 Years in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigational Site
525
mi
from 43215
Charleston, SC
Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis
A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Efficacy, Safety and Tolerability up to 5 Years in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigational Site
525
mi
from 43215
Charleston, SC
Click here to add this to my saved trials
Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis
A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Efficacy, Safety and Tolerability up to 5 Years in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
993
mi
from 43215
League City, TX
Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis
A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Efficacy, Safety and Tolerability up to 5 Years in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
993
mi
from 43215
League City, TX
Click here to add this to my saved trials
Preference Between Two Autoinjectors in Patients With Rheumatoid Arthritis and Plaque Psoriasis Treated With Etanercept
An Open-label, Randomized, Crossover Study to Assess the Preference for Autoinjector A Versus Autoinjector B in Rheumatoid Arthritis and Plaque Psoriasis Subjects Treated With Etanercept
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
410
mi
from 43215
Huntsville, AL
Preference Between Two Autoinjectors in Patients With Rheumatoid Arthritis and Plaque Psoriasis Treated With Etanercept
An Open-label, Randomized, Crossover Study to Assess the Preference for Autoinjector A Versus Autoinjector B in Rheumatoid Arthritis and Plaque Psoriasis Subjects Treated With Etanercept
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
410
mi
from 43215
Huntsville, AL
Click here to add this to my saved trials
Preference Between Two Autoinjectors in Patients With Rheumatoid Arthritis and Plaque Psoriasis Treated With Etanercept
An Open-label, Randomized, Crossover Study to Assess the Preference for Autoinjector A Versus Autoinjector B in Rheumatoid Arthritis and Plaque Psoriasis Subjects Treated With Etanercept
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
524
mi
from 43215
Tuscaloosa, AL
Preference Between Two Autoinjectors in Patients With Rheumatoid Arthritis and Plaque Psoriasis Treated With Etanercept
An Open-label, Randomized, Crossover Study to Assess the Preference for Autoinjector A Versus Autoinjector B in Rheumatoid Arthritis and Plaque Psoriasis Subjects Treated With Etanercept
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
524
mi
from 43215
Tuscaloosa, AL
Click here to add this to my saved trials
Preference Between Two Autoinjectors in Patients With Rheumatoid Arthritis and Plaque Psoriasis Treated With Etanercept
An Open-label, Randomized, Crossover Study to Assess the Preference for Autoinjector A Versus Autoinjector B in Rheumatoid Arthritis and Plaque Psoriasis Subjects Treated With Etanercept
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1970
mi
from 43215
Glendale, AZ
Preference Between Two Autoinjectors in Patients With Rheumatoid Arthritis and Plaque Psoriasis Treated With Etanercept
An Open-label, Randomized, Crossover Study to Assess the Preference for Autoinjector A Versus Autoinjector B in Rheumatoid Arthritis and Plaque Psoriasis Subjects Treated With Etanercept
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1970
mi
from 43215
Glendale, AZ
Click here to add this to my saved trials
Preference Between Two Autoinjectors in Patients With Rheumatoid Arthritis and Plaque Psoriasis Treated With Etanercept
An Open-label, Randomized, Crossover Study to Assess the Preference for Autoinjector A Versus Autoinjector B in Rheumatoid Arthritis and Plaque Psoriasis Subjects Treated With Etanercept
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1653
mi
from 43215
Scottsdale, AZ
Preference Between Two Autoinjectors in Patients With Rheumatoid Arthritis and Plaque Psoriasis Treated With Etanercept
An Open-label, Randomized, Crossover Study to Assess the Preference for Autoinjector A Versus Autoinjector B in Rheumatoid Arthritis and Plaque Psoriasis Subjects Treated With Etanercept
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1653
mi
from 43215
Scottsdale, AZ
Click here to add this to my saved trials
Preference Between Two Autoinjectors in Patients With Rheumatoid Arthritis and Plaque Psoriasis Treated With Etanercept
An Open-label, Randomized, Crossover Study to Assess the Preference for Autoinjector A Versus Autoinjector B in Rheumatoid Arthritis and Plaque Psoriasis Subjects Treated With Etanercept
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
666
mi
from 43215
Hot Springs, AR
Preference Between Two Autoinjectors in Patients With Rheumatoid Arthritis and Plaque Psoriasis Treated With Etanercept
An Open-label, Randomized, Crossover Study to Assess the Preference for Autoinjector A Versus Autoinjector B in Rheumatoid Arthritis and Plaque Psoriasis Subjects Treated With Etanercept
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
666
mi
from 43215
Hot Springs, AR
Click here to add this to my saved trials
Preference Between Two Autoinjectors in Patients With Rheumatoid Arthritis and Plaque Psoriasis Treated With Etanercept
An Open-label, Randomized, Crossover Study to Assess the Preference for Autoinjector A Versus Autoinjector B in Rheumatoid Arthritis and Plaque Psoriasis Subjects Treated With Etanercept
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1951
mi
from 43215
San Diego, CA
Preference Between Two Autoinjectors in Patients With Rheumatoid Arthritis and Plaque Psoriasis Treated With Etanercept
An Open-label, Randomized, Crossover Study to Assess the Preference for Autoinjector A Versus Autoinjector B in Rheumatoid Arthritis and Plaque Psoriasis Subjects Treated With Etanercept
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1951
mi
from 43215
San Diego, CA
Click here to add this to my saved trials
Preference Between Two Autoinjectors in Patients With Rheumatoid Arthritis and Plaque Psoriasis Treated With Etanercept
An Open-label, Randomized, Crossover Study to Assess the Preference for Autoinjector A Versus Autoinjector B in Rheumatoid Arthritis and Plaque Psoriasis Subjects Treated With Etanercept
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2083
mi
from 43215
San Ramon, CA
Preference Between Two Autoinjectors in Patients With Rheumatoid Arthritis and Plaque Psoriasis Treated With Etanercept
An Open-label, Randomized, Crossover Study to Assess the Preference for Autoinjector A Versus Autoinjector B in Rheumatoid Arthritis and Plaque Psoriasis Subjects Treated With Etanercept
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2083
mi
from 43215
San Ramon, CA
Click here to add this to my saved trials
Preference Between Two Autoinjectors in Patients With Rheumatoid Arthritis and Plaque Psoriasis Treated With Etanercept
An Open-label, Randomized, Crossover Study to Assess the Preference for Autoinjector A Versus Autoinjector B in Rheumatoid Arthritis and Plaque Psoriasis Subjects Treated With Etanercept
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2062
mi
from 43215
Santa Maria, CA
Preference Between Two Autoinjectors in Patients With Rheumatoid Arthritis and Plaque Psoriasis Treated With Etanercept
An Open-label, Randomized, Crossover Study to Assess the Preference for Autoinjector A Versus Autoinjector B in Rheumatoid Arthritis and Plaque Psoriasis Subjects Treated With Etanercept
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2062
mi
from 43215
Santa Maria, CA
Click here to add this to my saved trials
Preference Between Two Autoinjectors in Patients With Rheumatoid Arthritis and Plaque Psoriasis Treated With Etanercept
An Open-label, Randomized, Crossover Study to Assess the Preference for Autoinjector A Versus Autoinjector B in Rheumatoid Arthritis and Plaque Psoriasis Subjects Treated With Etanercept
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1958
mi
from 43215
Tustin, CA
Preference Between Two Autoinjectors in Patients With Rheumatoid Arthritis and Plaque Psoriasis Treated With Etanercept
An Open-label, Randomized, Crossover Study to Assess the Preference for Autoinjector A Versus Autoinjector B in Rheumatoid Arthritis and Plaque Psoriasis Subjects Treated With Etanercept
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1958
mi
from 43215
Tustin, CA
Click here to add this to my saved trials
Preference Between Two Autoinjectors in Patients With Rheumatoid Arthritis and Plaque Psoriasis Treated With Etanercept
An Open-label, Randomized, Crossover Study to Assess the Preference for Autoinjector A Versus Autoinjector B in Rheumatoid Arthritis and Plaque Psoriasis Subjects Treated With Etanercept
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1162
mi
from 43215
Denver, CO
Preference Between Two Autoinjectors in Patients With Rheumatoid Arthritis and Plaque Psoriasis Treated With Etanercept
An Open-label, Randomized, Crossover Study to Assess the Preference for Autoinjector A Versus Autoinjector B in Rheumatoid Arthritis and Plaque Psoriasis Subjects Treated With Etanercept
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1162
mi
from 43215
Denver, CO
Click here to add this to my saved trials